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ABSTRACT 
 
 
The skeleton is formed via intramembranous ossification and endochondral ossification. 
Endochondral ossification, which is the focus of this research, is the process by which the long 
bones of the skeleton undergo chondrogenesis followed by osteogenesis. The objective of this 
project is to define the genetic profiles of two types of clastic cells in endochondral ossification: 
osteoclasts and chondroclasts, which are responsible for breaking down bone and calcified 
cartilage, respectively. The goal of this project is to validate the hypothesis that these two very 
similar cells types, which arise from a common precursor, are distinguished by a pattern of 
differentially expressed genes in response to the interaction with the two different 
microenvironments in which these cells are found. In order to carry out this experiment, E18.5 
embryos were sectioned and stained for tartrate-resistant acid phosphatase (TRAP). TRAP-
positive cells were captured using laser capture microdissection. Cells were then lysed so that the 
RNA could be isolated and transcribed to cDNA, which was linearly amplified, so that qPCR 
could be performed. A list of candidate genes was chosen for qPCR analysis. Results indicated 
that there are differences in the expression profiles between chondroclasts and osteoclasts. These 
results supported the hypothesis that chondroclasts and osteoclasts have distinct genomic profiles 
at timepoint E18.5 during embryonic development. Identifying and testing the functional 
differences in the genomic profile of these two cell types will be instrumental in developing new 
strategies to target these cells in diseases such as osteoarthritis and osteoporosis.  
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INTRODUCTION 
 
Skeletal Formation During Embryogenesis 
Skeletal development during embryogenesis requires the coordination of multiple 
programs including cellular growth, differentiation, apoptosis, extracellular matrix remodeling, 
and angiogenesis. The skeleton is formed via two processes: intramembranous ossification and 
endochondral ossification. The flat bones of the skull, scapulae, pelvic bone are formed through 
intramembranous ossification while the appendicular and axial skeleton are formed through 
endochondral ossification. These two processes both begin with the differentiation of 
mesenchymal stem cells. Mesenchymal stem cells are multipotent cells that can differentiate into 
many different cell lineages (i.e. bone, fat, muscle, cartilage, tendon and marrow stroma) (1). In 
both intramembranous and endochondral ossification, the mesenchymal stem cells first aggregate 
at the location of the future skeleton, to form mesenchymal condensations. In intramembranous 
ossification, the mesenchymal stem cells are derived from the neural crest of the cranium. The 
cranial neural crest-derived mesenchymal stem cells proliferate and are condensed into nodules 
and differentiate into osteoblasts. During this process, the osteoblasts also secrete a collagen-
proteoglycan matrix that becomes calcified and vascularized and ultimately forms the osteoid 
matrix (2).  
Endochondral ossification is the process by which the long bones of the skeleton are 
formed. Unlike intramembranous ossification, bones formed by endochondral ossification 
undergo a chondrogenic stage as well as an osteogenic stage. Thus endochondral ossification 
presents an orderly progression during which cartilage, which is a predominantly avascular tissue 
is replaced by bone, which is one of the most highly vascularized tissues in the body. In 
endochondral ossification during development, mesenchymal stem cells condense at sites that 
will eventually form the appendicular skeleton. These condensations take the form of the bones 
that will develop at these sites. Shortly after the condensation, the mesenchymal stem cells 
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undergo differentiation along the chondrogenic pathway to form chondrocytes. The resulting 
cartilaginous bone templates are called anlagen. The chondrocytes in the anlagen then undergo a 
further differentiation resulting in hypertrophy, which is marked by the expression of Type 10 
collagen. The hypertrophic chondrocytes become surrounded by a calcified extracellular matrix, 
which is invaded by blood vessels from the perichondrium. At this time, another type of cell is 
recruited to the bone, a clastic cell that differentiates from the hematopoietic stem cells through 
the monocyte/macrophage lineage. Following this vascular invasion, the hypertrophic 
chondrocytes die through apoptosis and pre-osteoblasts, which also develop from the 
mesenchymal stem cells in the perichondrium adjacent to the hypertrophic chondrocytes 
differentiate and become osteoblasts. These osteoblasts deposit the bony extracellular matrix to 
generate the bone collar, whose extracellular matrix is characterized by Type I collagen, which 
again becomes calcified. At the same time that these osteoblasts stay on the periphery of the bone, 
others migrate into the center of the anlagen to form the beginning of the primary spongiosa, the 
precursor of trabecular bone. 
This process of primary ossification, whereby osteoblasts replace chondrocytes, proceeds 
down the bone until the only remaining chondrocytes are confined to the growth plate at the ends 
of the bone. During this time, other clastic cells that arise from the monocyte/macrophage lineage 
are recruited to the developing bone and begin to break down the bony extracellular matrix in the 
process of bone remodeling, which will continue throughout the life of the animal. This 
remodeling of the bony matrix results in a cavity filled with vascular channels containing 
hematopoietic cells. 
The timing of this whole ossification process is relatively rapid. In the mouse, the hyaline 
cartilage begins to form around embryonic day E12.5. At around E14.5, the hyaline cartilage 
begins to undergo proliferation and form the anlagen model of the bone. Chondrocytes in the 
anlagen then undergo hypertrophy and the differentiated chondrocytes eventually form the 
cartilaginous matrix. At around E16.5 this matrix then gets invaded by blood vessels, osteoclasts, 
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bone marrow cells and osteoblast precursor cells to form the primary ossification center (3). As 
the cartilage matrix gets removed by clastic cells, osteoblasts lay down bone in place of the 
cartilage and the primary ossification center expands away from the mid-shaft of the bone (4) at 
E18.5. Finally at around E20.5, immediately before birth, the remaining cartilage is restricted to 
the articular cartilage and the epiphyseal growth plate. 
 
Osteoclasts and Chondroclasts: Cells that Break Down Mineralized Matrix 
My research focuses on the cells that resorb mineralized matrix of hard tissues, otherwise 
known as clastic cells. Clastic cells, which include osteoclasts and chondroclasts, are responsible 
for breaking down bone and calcified cartilage, respectively. Clastic cells arise from pluripotent 
hematopoietic stem cells, which differentiate to form myeloid stem cells, which then differentiate 
and proliferate into granulocytes, monocytes and megakaryocytes (5). Of these myeloid stem 
cells, granulocytes (which are granulocyte-macrophage colony-forming cells) are the earliest 
hematopoietic precursor to the clastic cells (6). Of the two types of clastic cells, osteoclasts are 
more well-known and well-studied. Osteoclasts are characterized as giant, multinucleated cells 
required for maintaining bone homeostasis (7). In order for osteoclasts to mature and become 
active, they must be stimulated by cytokines known as receptor activator of nuclear factor kappa-
B ligand (RANKL) and macrophage colony stimulating factor (MCSF) (7, 8) RANKL, a 
regulatory receptor found on the surface of osteoblasts, interacts with its receptor RANK, found 
on the surface of osteoclasts and their progenitors, to initiate this process of osteoclastic 
differentiation. During the process of bone resorption, the clastic cell adheres to the bone surface 
and forms a microenvironment that is separate from the extracellular space. This isolation is 
carried out by what’s known as the sealing zone. Adjacent to this sealing zone is the ruffled 
membrane or border (9). The ruffled border is a complex structure that is formed when lysosome-
derived vesicles are inserted into the bone-apposed plasma membrane (10, 11). It contains ions 
and charged channels that allow for the transport of acids such as HCl into the resorptive space, 
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which acidifies the bone area, releasing mineral, and exposes its organic matrix. This organic 
matrix is then degraded by Cathepsin K, another enzyme that is secreted from the ruffle border 
(9). 
 
Chondroclasts: Clastic Cells that Resorb Cartilage Matrix 
Chondroclasts, like osteoclasts, are multinucleated cells that appear on the surface of 
mineralized cartilage. In addition to being multinucleated, chondroclasts also express tartrate-
resistant alkaline phosphatase (TRAP) activity and other cytokines such as metalloproteinase 
MMP9 and Cathepsin K (12). They also have ruffled-border membranes that are less developed 
than those of osteoclasts and are found on non-mineralized transversal septae whereas osteoclasts 
are found on mineralized longitudinal trabeculae (13).  Previous research has identified 
chondroclasts and osteoclast as different cells that arose from the same hematopoietic precursor 
(14); however, their relationship to matrix resorbing cells and macrophages in development and 
diseased models (i.e. rheumatoid arthritis), is not well understood (15). There has also been 
debate as to whether chondroclasts are the same cells as osteoclasts or whether they are unique 
cells, separate from osteoclasts. Research performed by Knowles HJ 2012 suggested that 
chondroclasts and osteoclasts share many of the same phenotypic features (15). However another 
study suggested that chondroclasts and osteoclasts differ when semi-quantitative estimation of 
TRAP was performed in both cell types (16). These results showed an inverse relationship 
between the extracellular and intracellular TRAP in chondroclasts and osteoclasts (16). A third 
study observed chondroclasts in osteogenesis by implanting demineralized bone powder into the 
rectus abdominis of rats (17). This study found that giant polykarions in the implant after the 
cartilage matrix was calcified. They determined that these polykarions were chondroclasts 
resorbing cartilage (17). Despite these opposing views of chondroclasts, there is no doubt that 
they are cells that are intimately involved in endochondral ossification and are morphologically 
and histochemically similar to osteoclasts (12). 
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 Work done previously by the Drissi/Hansen laboratories had examined the question of 
the similarity of the chondroclast and osteoclast during fracture healing (18). They determined 
that there were differences in patterns of genomic expression between chondroclasts and 
osteoclasts that were consistent with these two populations of TRAP-positive cells being distinct 
in the context of pathological fracture healing.  
 
Defining the Chondroclast in Development 
My research project focused on the process of endochondral ossification during mouse 
fetal development. In particular, my research tested whether the TRAP-positive cells found in the 
developing mineralized cartilage (chondroclasts) and in the developing mineralized bone 
(osteoclasts), during embryonic development, had similar or distinct gene expression profiles. 
While it is possible that the gene expression profiles of the chondroclast and osteoclast would be 
similar, it is also possible that these two cell types show distinct differences in expression based 
on their response to the cellular microenvironment that they encounter during endochondral 
ossification during development.  
 
Hypothesis 
My research hypothesizes that TRAP-positive chondroclasts and osteoclasts are distinct cell types 
that play different roles in skeletal development and are distinguished by unique patterns of 
differentially expressed genes. Identification of the genomic signatures of these two types of 
clastic cells can be used to examine the signals that cause a common precursor stem cell to give 
rise to these separate cell types. This difference in pattern of genomic expression profiles would 
likely reflect differences in the cellular microenvironment of the hypertrophic chondrocytes and 
the osteoblast. In turn, these experiments will allow us to identify genes that are important in 
defining the osteoclast and chondroclast cells in development. 
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MATERIALS AND METHODS 
 
Timed Embryos/Samples: 
E18.5 embryos were obtained courtesy of the H. Drissi and C. Dealy laboratories (19).  
 
Embryonic Mouse Tissue Processing and Paraffin Embedding:  
Using the Kosher and Dealy laboratories protocol, embryos were fixed in fresh-made 
paraformaldehyde in 1xPBS overnight at 4° C. All solutions were made in autoclaved DEPC 
water.  
Embryos that are E16.5 and older must be decalcified after paraformaldehyde fixation at 
4° C on a rocker. Embryos were first placed in PBS for 2 changes of 30 seconds then decalcified 
in 15% EDTA in PBS for 24 hours. They were then placed in PBS for 2 changes of 30 seconds, 
0.9% NaCl for 2 changes of 30 seconds, 30% Ethanol for 1 hour, 50% Ethanol fo1 1 hour, and 
70% for 1 hour. Embryos were stored in 70% Ethanol prior to processing.  
Embryos were then processed in PBS for 2 changes of 30 seconds, 0.9% NaCl in DEPC 
water for 2 changes of 30 seconds, 30% Ethanol for 1 hour, 50% Ethanol fo1 1 hour, and 70% for 
1 hour. Embryos were stored in 70% Ethanol in the freezer prior to paraffin embedding. 
Paraffin embedding was done for E18.5 embryos in 95% Ethanol for 45 minutes, 100% 
Ethanol for 3 changes at 30 mins each, 100% Ethanol and Xylene for 30 minutes, Xylene for 3 
changes at 30 minutes each, Xylene and Paraffin for 30 minutes and finally, in Paraffin for 4 
changes at 45 minutes each under vacuum. 
 
Immunohistochemistry & Immunocytochemistry: 
Hematoxylin and Eosin (H&E) stain was used to identify clastic cells as multinucleated 
cells on sectioned embryos. The resulting stain showed the nuclei as blue and the cytoplasm as 
pink/red. I stained sections (7µm thick) from the femur and humerus of E18.5 embryos to identify 
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tartrate-resistant acid phosphatase (TRAP)-positive cells (K-ASSAY, Kamiya Biomedical 
Company). TRAP activity was detected using a colorimetric assay in which TRAP acts by 
cleaving the phosphate group from a substituted naphthol AS phosphate (Naphthol-AS-BI-
phosphoric acid) to form naphthol-AS. This unstable product acts on a diazonium salt to generate 
an azoic dye which is deposited as a red stain on the TRAP-positive cells. Alcian Blue stain was 
used to counter-stain in order to identify hyaline and hypertrophic cartilage.  
 
Laser Capture Microdissection:  
It is critical that the chondroclast and osteoclast cells be collected as homogenous populations of 
cells. To do this, I used Laser Capture Microdissection (LCM) to capture individual cells from 
sections of the embryonic femur and humerus. LCM was performed with a PixCell II laser 
capture microdissection system (Life Technologies, Carlsbad, CA). Briefly, mouse embryos from 
18.5dpc were collected, fixed in 4% formalin and embedded in paraffin. Serial 7µm sections were 
cut from each embryo and placed on uncharged microscope slides. The individual slides were 
stained for TRAP activity as discussed above. The slides were then serially dehydrated in 50% 
Ethanol for 5 minutes, 70% Ethanol for 5 minutes, 90% Ethanol for 10 minutes, 100% Ethanol 10 
minutes and Xylene for 10 minutes. Laser capture microdissection was performed using a 7.5 µm 
laser spot with 100 mW power and 3.4 ms pulse duration. Individual TRAP-positive cells from 
the developing cartilage and developing bone were observed under 200X magnification and 
captured on Arcturus CapSure Macro LCM Caps (Life Technologies). Following capture, the 
individual caps were placed into Eppendorf tubes and stored at -20 degrees Celsius, until RNA 
isolation.  
 
Lysis of RNA:  
RNA was taken from each LCM cap containing 10 cells, either chondroclasts or osteoclasts. 
Capture and lysis was performed in triplicates using cells captured from different, wildtype 
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embryos. Since each capture involved only 10 cells, the amount of RNA to be isolated was very 
small. This required a number of steps, in which RNA lysis was followed by linear amplification 
of the RNA. RNA was lysed and amplified from the TRAP-positive cells using a modified 
version of the Single Cell Transcript Analysis, as previously described (20). Briefly, cells from 
each cap were lysed using 5% NP-40, RNAsin plus (Promega #N2611), PBS in the presence of a 
pool of gene-specific SYBR Green Primers (200 nM). Cells were denatured in thermocycler at 70 
degrees Celsius for 10 minutes and 4 degrees Celsius for 5 minutes.  
 
Reverse transcription:  
The RNA was reversed transcribed using the ABI High Capacity cDNA Reverse Briefly, the 
transcription mixture included a 10X RT buffer, 25X dNTP mix (final concentration of 100 mM), 
10X RT Random Primers, Multiscribe Reverse Transcriptase, RNAse Inhibitor and Nuclease free 
water. The reverse transcription was performed using a thermocycler with a program of 37 
degrees Celsius for 2 minutes, 42 degrees Celsius for 1 min, 50 degrees Celsius for 40 cycles. The 
mixture was heated to 85 degrees Celsius for 5 minutes and held at 4 degrees Celsius and stored 
at -20.`. 
 
Pre-Amplification:  
Following lysis of the cells and reverse transcription of the RNA, it was necessary to linearly 
amplify the cDNA prior to analysis by qPCR. The cDNA pre-mixture was amplified using a Pool 
of SYBR Green primers (200 nM), UltraPure water, and Takara PCR Premix and Taq polymerase 
(#R004A). This was performed in a thermocycler with a program at 95 degrees Celsius for 3 
minutes, 55 degrees for 2 minutes and 72 degrees Celsius for 2 minutes, then 95 degrees Celsius 
for 15 seconds, 60 degrees Celsius for 2 minutes and 72 degrees Celsius for 2 minutes for 16 
cycles. Following the amplification, the mixture was held at 4 degrees Celsius and stored at -20. 
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RT-qPCR analysis:  
During the process of formalin-fixation, paraffin-embedding followed by LCM extraction and 
cell lysis and RNA linear amplification, the amplified product was highly degraded to 
approximately 100-120 bps. This necessitated using specific primers for qPCR analysis (Table 
1). The primer pairs needed to have an amplified product of about 100 nucleotides or less.  
The linearly amplified cDNA was now ready for gene-specific qPCR. Briefly, a total of 4 µg of 
each triplicate amplified cDNA sample was used as template. A single qPCR master mix was 
prepared for each sample consisting of the 4 µg cDNA and iTaq Universal SYBR Green 
Supermix (Life Technologies, Grand Island, NY).  10 µl qPCR reactions consisting of 
approximately 20 ng of cDNA equivalent were run in 96-well plates using an Applied Biosystems 
7500 Real-Time PCR System (Bio-Rad Laboratories).  
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Table 1: Genes and their Specific Primers  
Gene Amplicon 
size 
 
Primer Bank 
ID 
 
Sequence (F and R) 
Ubiquitin 76 212275974c1 F: CCCACGTCGGAGAACTTAACA 
R: GACAAGCAGCCGGGATAGAAG 
Sp7 93 148747346c2 F: TCCCTGGATATGACTCATCCCT 
R: CCAAGGAGTAGGTGTGTTGCC 
COL10A1 77 158187527c3 F: GGGACCCCAAGGACCTAAAG 
R: GCCCAACTAGACCTATCTCACCT 
Gapdh 83 6679938c3 F: TTGTCATGGGAGTGAACGAGA 
R: CAGGCAGTTGGTGGTACAGG 
Zfp595 102 29244006a1 F: GGGGGAAAAGCTATACGTGTAAA 
R: ACTTGCAGGACTTCACTCCTAAA 
Higd2a 78 146135032c1 F: CCCCAGTTATCGAGGGCTTC  
R: GGGTCTTGCGAATAAACTTTTCC 
Psmb9 106 118129789c3 F: ACCGTGAGGACTTGTTAGCG 
R: GTAAAGGGCTGTCGAATTAGCA 
Mdga2 95 300863062c3 F: CATTGCTTCAGTAAGGAACGTGT 
R: CCAAGAGCTTAATTGACGGAGAA 
Myo1D 87 118026910c2 F: TGGGAGGGACACTGTCGAG 
R: TTGTAAGCAGCGTCAGCAATA 
Thrsp 63 31560631c1 F: ATGCAAGTGCTAACGAAACGC  
R: GGAGTACCGATCCATGACTGTC 
Hic1 97 148228528c3 F: ACTCCAGACCCGTTTCGAG  
R: CGTGCTTCATCCAGCGGTA 
Wnt5a 77 371940978c1 F: CAACTGGCAGGACTTTCTCAA 
R: CCTTCTCCAATGTACTGCATGTG 
Ufsp2 83 20149753c2 F: TTGACGCCGTTGTGTCTGTT 
R: TAGCTGCCTGAGAATTGCATC 
Dot1L 112 40556380c1 F: GAGGCTCAAGTCGCCTGT 
R: GACCCACCGGATAGTCTCAAT 
P2rx5 75 238624117c1 F: GCTCACCATCCTGTTGTACTTAC 
R: AGGGAAGTGTCAATGTCCTGA 
Nxn 102 162287186c2 F: GGCTCCTGGTGATCCGAGAT 
R: GCCCGTTATTTCTAAGCAAGGG 
Psat1 90 329299027c2 F: AAGGAGTGCTGACTACGTGGT 
R: GGGTGGACAATGTTCACGTT 
Aldh3a1 80 163310770c3 F: TCCAGCGGGTCATAAATCTGA  
R: AGCTATGTATCGTGAAGGCTGAT 
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Normalization and Comparison of Relative Gene Expression: 
qPCR data for each gene was normalized to compare relative expression levels between 
chondroclasts and osteoclasts via quantitative ΔΔCt analysis. The mean Ct values of the 
collective endogenous controls were used for internal normalization. Mean relative fold induction 
was calculated using the Comparative CT Method (ΔΔCt Method) from Applied Biosystems (21). 
For each sample, the mean Ct for each test gene was subtracted from the mean Ct value for the 
endogenous control (β-Actin). This gave the ΔCt for each sample and gene. The standard error 
was then calculated as the square root of the sum of the square of the standard deviation divided 
by the square root of the number of samples. The ΔΔCt was calculated by subtracting the ΔCt of 
the osteoclast from the ΔCt of the chondroclast. Finally, the relative fold change was calculated as 
2-ΔΔCt for each gene. The error bars were calculated as +/- the standard error for the ΔΔCt and 
calculated as 2-ΔΔCt+SE and 2 -ΔΔCt -SE.  
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RESULTS 
 
TRAP Staining to Identify Chondroclasts and Osteoclasts on Histological Sections of E18.5 
Mouse Embryos 
E18.5 embryos were sectioned, deparaffinized and stained for TRAP. TRAP stain was left on 
each section for 12-20 minutes until TRAP-positive cells became identifiable under the 
microscope. The sections were then counterstained with Alcian Blue, which stains the cartilage. 
This was done in order to make it easier to distinguish between chondroclasts and osteoclasts 
based proximity to cartilage and bone, respectively. Figure 1 shows a section from an E18.5 
femur that has been stained for TRAP and counterstained with Alcian Blue. As shown in this 
figure, chondroclasts were located on or near hypertrophic chondrocytes and osteoclasts were 
located on mineralized bone. There were a number of TRAP-positive cells that were not 
associated with either cartilage or bone. These were not captured as it was unclear whether these 
would be chondroclasts or osteoclasts.  
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Figure 1: 200X photograph of a TRAP stained section from an E18.5 femur, 
counterstained with Alcian Blue (which stains cartilage). Pink arrows denote TRAP-
positive (red-stained) chondroclasts sitting on and around hypertrophic cartilage. Green 
arrows denote TRAP-positive (red-stained) osteoclasts sitting on the bone and away from 
the bone marrow cavity. Black arrows denote TRAP-positive cells that were neither 
adjacent to the hypertrophic cartilage nor adjacent to bone that were not collected.  
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LCM to Capture Homogenous Population of Chondroclasts and Osteoclasts 
Once TRAP-positive chondroclasts and osteoclasts had been located, the cells were captured 
using LCM. This technology allows for the isolation of individual cells, directly from the sample 
without pulling up too much unwanted material from the region around the desired cell. LCM 
facilitates capture of homogenous populations of cells. Figure 2 illustrates the LCM microscope 
that was used to captured and collect cells. Figure 3 depicts the before, during and after the 
capture of a cell. For chondroclasts and osteoclasts, I captured 10-20 individual cells 
(chondroclasts or osteoclasts) on each cap and stored the caps at -20 degrees Celsius prior to 
RNA lysis.  
 
 
 
Figure 2: Main components of laser capture microdissection and how 
it is performed. 1. Laser Housing 2. Dock for slide 3. Joystick to move 
dock 4. Arm to hold, pick up and move the LCM cap.  
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A 
     
Before Capture                           During Capture                          After Capture                
 
B 
     
Before Capture                           During Capture                          After Capture 
 
Figure 3: (A) LCM showing before, during and after capture of a TRAP positive osteoclast 
(B) LCM illustrating before, during and after capture of a TRAP-positive chondroclast. In 
both A and B, note the ring of melted polymer surrounding the cell to be captured. In the after 
capture, the TRAP-positive cell has been removed.  
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RT-qPCR for Endogenous Controls and Known Markers for Osteoblast and Hypertrophic 
Chondrocyte Expression 
The first step of the project was to isolate, amplify, and assess levels of genes that were 
ubiquitously expressed in all cells of the mouse, in order to test the quality of the RNA that had 
been collected from the TRAP-positive cells. To do this, I chose three genes as my endogenous 
controls; glyceraldehyde 3-phosphate dehydrogenase (Gapdh), β-Actin (Actb) and Ubiquitin C 
(Ubc) (Table 2). In addition to my endogenous controls, I also performed qPCR for two markers 
known to be specific for osteoblast and hypertrophic chondrocyte cells (Table 3) (22, 23), in 
order to rule out contamination of the samples that I collected.  
RT-qPCR analysis allows relative quantitation of RNA levels present in the cells. The 
relative quantitation relies on the determination of the cycle threshold. The cycle threshold is the 
number of rounds of PCR amplification (cycles) necessary for the fluorescent signal created by 
incorporation of fluorescent labeled nucleotides into the PCR product to cross a predetermined 
threshold. The lower the Ct number, the higher the concentration of RNA in the sample. 
After running qPCR for the endogenous controls and analyzing the cycle threshold (Ct) 
values, I found that the Ct values for the endogenous genes were between 15 and 23 (Figure 3). 
These values showed that my RNA samples had been successfully amplified. This was important 
because all of the steps required to collect the RNA were heavily damaging to the RNA, yet I was 
successful in obtaining usable RNA for my analyses.   
The other critical question in this initial qPCR test was the potential level of 
contamination of the TRAP-positive cells by chondrocytes and osteoblasts. After running the 
qPCR, I analyzed the Ct values for Sp7, an osteoblast marker gene, and Col10A1, a chondrocyte 
marker gene. I saw that the Ct values for Sp7 were greater than 30 (Figure 4). Ct values greater 
than 30 suggest that very little Sp7 RNA in the samples. This suggests that there was little 
osteoblast contamination in the clastic cell samples that I collected. However, for my Col10A1 
analysis, which is a marker for hypertrophic chondrocytes, the Ct value fell below the Ct 30 
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threshold, raising concerns regarding contamination. To further rule out contamination, I isolated 
hypertrophic chondrocytes by LCM, extracted RNA from cells and compared levels of expression 
of Col10A1 from the chondrocytes to the level of expression in my chondroclast samples. 
Comparing expression between the chondrocyte and chondroclast, I saw that there was a 230-fold 
increased expression of Col10A1 in the chondrocyte samples relative to the chondroclast samples 
(Table 4). This suggested that there was minimal contamination of my chondroclast samples by 
hypertrophic chondrocytes.  Having ruled out contamination and chosen to use β-Actin as my 
endogenous control, I was now able to run my qPCR for my candidate genes.  
Genes Full name/Protein Function 
Gapdh 
Glyceraldehyde  
3-phosphate 
dehydrogenase  
 Involved in transcription, RNA transport, DNA 
replication and apoptosis 
Actb Beta-Actin  Involved in cell motility and are ubiquitously expressed in all eukaryotic cells 
Ubc  
 
Ubiquitin C 
 Associated with protein degradation, DNA repair, 
cell cycle regulation, kinase modification, 
endocytosis, and regulation of other cell signaling 
pathways 
 
Table 2: Potential Endogenous Control Genes 
Genes Gapdh, B-Actin and Ubc are the endogenous control genes that are ubiquitously 
expressed in the cells of mouse. 
 
Genes Full name/Protein Function 
Col10A1 Collagen, Type X, Alpha 1 
Short chain collagen expressed by hypertrophic 
chondrocytes during endochondral ossification 
Sp7 Zinc Finger Protein Osterix 
 Bone specific transcription factor required for 
osteoblast differentiation and bone formation 
 
Table 3: Known Markers of Chondrocyte and Osteoblast Cells 
Genes Col10A1 and Sp7/Osterix, are known markers for hypertrophic cartilage and osteoblast, 
respectively (22, 23) 
1 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Gene information was obtained from GeneCards®: The Human Gene Database 
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Figure 4: Expression of three different housekeeping genes in RNA from LCM-captured 
chondroclast and osteoclast samples. Ct values represent the number of qPCR cycles it takes 
for a signal to be detected. The lower the Ct value, the more RNA of that gene in the sample. Ct 
values of 15-23 suggest good yields of RNA in the samples.  
CCL – chondroclast; OCL - osteoclast 
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Figure 5: Expression of known markers for osteoblasts and hypertrophic chondrocytes. Sp7 
expression in chondroclasts and osteoclasts had Ct values >30, while Ct values for the 
endogenous controls (Actb) were ≤17 (Figure 3), which suggested very low to no expression 
of Sp7 in the chondroclast/osteoclast samples, consistent with very low to no contamination 
of osteoblasts in either LCM-captured sample. Ct values for Col10A1 expression in the 
osteoclast samples were also in excess of 30, which suggested low to no contamination of 
hypertrophic chondrocytes in the LCM-captured osteoclast samples. However, Ct values for 
Col10A1 in the chondroclast samples were in the 27-28 range, which required additional 
analysis to determine whether this expression was consistent with a possible significant level 
of contaminating chondrocytes.  
CCL – chondroclast; OCL - osteoclast 
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 COL10A1 B-Actin ΔCt ΔΔCt Fold Expression 
CCL 28.003 
 
17.19 
 
10.81 
 
 
7.85 
 
 
230 
HC 
 
28.816 
 
25.84 
 
2.98 
 
Table 4: Relative quantitation of Col10A1 expression in chondroclasts and hypertrophic 
chondrocytes. Quantitative comparison of expression using the ∆∆Ct method was done to 
determine the possible levels of contamination of chondrocytes in the chondroclast samples. 
There was a 230-fold greater level of expression of Col10A1 in the RNA from the hypertrophic 
chondrocytes than in the chondroclasts when normalized to Actb expression suggesting that 
there was little to no expression of Col10A1 in the CCL samples and thus the data were 
consistent with little to no contamination of the CCL samples by chondrocytes.  
CCL – chondroclast; HC – hypertrophic chondrocyte 
 
 
RT-qPCR Analysis Using a Candidate Gene Approach  
The thirteen candidate genes selected for my analysis were chosen from among those that had 
been found to be differentially expressed between chondroclasts and osteoclasts in a mouse 
fracture model (Table 5). I wanted to test whether these genes were differentially expressed 
between chondroclasts and osteoclasts in the developing mouse.  Each gene was tested in each of 
three independent LCM-captured samples of chondroclasts and osteoclasts. qPCR analysis of the 
RNA from the chondroclasts and osteoclasts samples for the selected genes revealed Ct values 
between 18 and 32 (Figure 5). 
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Genes Full name/Protein Function 
Zfp595  Zinc finger protein 595  DNA template-transcription  
Aldh3a1  Aldehyde Dehydrogenase 3 Family, Member A1 
Detoxification of alcohol-derived 
acetaldehydes; involved in metabolism of 
corticosteroids, biogenic amines, 
neurotransmitters and lipid peroxidation 
Psmb9/Lmp2  Proteasome Subunit Beta 9 
Cleaves peptides in an ATP/ubiquitin-
dependent process; the modified 
proteasome processes class I MHC 
peptides 
Thrsp  Thyroid hormone-inducible hepatic protein 
Regulation of lipogenesis (lactating 
mammary glands) 
Hic1  Hypermethylated in cancer 1 protein  
Growth regulatory and tumor suppressor  
Mdga2  
MAM domain containing 
glycosylphosphatidylinositol 
anchor 2 
 Required for radial migration of cortical 
neurons; maintenance of inhibitory 
synapses 
Dot1L  
DOT1-like, histone H3 
methyltransferase (S. 
cerevisiae) 
 Histone methyltransferase that methylates 
lysine-79 of histone H3 
P2rx5 Purinergic Receptor P2X, Ligand Gated Ion Channel, 5 
Ligand-gated ion channel. Alternative 
splicing results in multiple transcripts 
Nxn Nucleoredoxin 
 Redox-dependent regulator of the Wnt 
signaling pathway; involved in cell growth 
and differentiation 
Ufsp2 UFM1-Specific Peptidase 2 
  A thiol protease that processes the C 
terminus of ubiquitin-fold modifier 1 
(UFM1) 
Wnt5a 
Wingless-Type MMTV 
Integration Site Family, 
Member 5A 
 Involved in oncogenesis and 
developmental processes (regulation of cell 
fate and patterning during embryogenesis) 
Myo1D Myosin ID  Actin –based motor molecules with ATPase activity 
Higd2A HIG1 Hypoxia Inducible Domain Family, Member 2A 
 Contains a subunit of cytochrome c 
oxidase that catalyzes the reduction of 
oxygen to water  
 
Table 5: Candidate Genes. Genes shown here were some of the most differentially expressed 
genes between OCL and CCL in the fracture mouse model.  
2 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Gene information was obtained from GeneCards®: The Human Gene Database 	  
	   22	  
 
 
Figure 6: Ct values for candidate genes in chondroclasts and osteoclasts in the E18.5 
embryo. The efficiency of the amplification of each gene is relatively equal to that of the 
amplification of the endogenous control (Actb).  
CCL – chondroclasts; OCL - osteoclasts 
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Relative Quantitation of Gene Expression by ΔΔCt Method: 
The ΔΔCt method of relative quantitation can be used to compare differences in relative 
levels of expression of genes (21). We used this method to compare levels of gene expression 
between chondroclasts and osteoclasts for thirteen genes. To do this, ΔCt values were obtained by 
subtracting the mean Ct values of the endogenous control gene (Actb) from the experimental 
gene. This analysis is considered best used when the Ct values for the endogenous control are 
similar to values of the experimental gene. ΔΔCt values are obtained by subtracting the mean 
osteoclast ΔCt value from the mean chondroclast ΔCt value. The log ΔΔCt values of all thirteen 
genes tested are shown in Figure 6. Negative values correspond to increased relative expression 
in chondroclasts while positive values correspond to increased relative expression in osteoclasts. I 
then calculated the relative fold difference of expression between the chondroclasts and 
osteoclasts using the formula 𝑅𝐹 = 2!∆∆!". The results are plotted in Figure 7. Together, these 
data indicate that the gene expression profile of osteoclasts and chondroclasts is different. 
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Figure 7: Log fold expression ratio for E18.5, calculated using Comparative ∆∆Ct Method 
(citation needed). Negative ∆∆Ct values mean that the gene is more highly expressed in 
chondroclasts. Positive ∆∆Ct values mean that the gene is more highly expressed in 
osteoclasts.  
CCL – chondroclast; OCL - osteoclast 
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Figure 8: Mean relative fold induction for chondroclasts and osteoclasts in the E18.5 
embryo. Relative fold induction is calculated as: RF=2-∆∆Ct  
CCL – chondroclasts; OCL - osteoclasts 
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DISCUSSION 
 
 
Remodeling of mineralized cartilage is an essential step in the process of endochondral 
ossification that occurs during development (Figure 9). The term chondroclast has been assigned 
to the multi-nucleated TRAP-positive cells found near hypertrophic cartilage, with the unique 
function of remodeling mineralized cartilage matrix. While it is generally believed that both 
osteoclasts and chondroclasts arise from the same monocyte/macrophage precursor, it is not 
known what causes these two clastic cells to differentiate into two different cell types. However, 
it is likely that the signal to differentiate into the two different clastic cells comes from the unique 
microenvironments into which these two cells invade. 
 
Figure 9. Critical role for chondroclasts in remodeling mineralized cartilage during 
endochondral ossification. The chondroclasts provide routes for the vascularization of the 
mineralized hypertrophic chondrocytes that in turn will allow invasion of osteoblasts and 
subsequent ossification (24).  
 
While the genes necessary for osteoclastogenesis have been widely characterized (25) 
little is known about the genetic similarities or differences between osteoclasts and chondroclasts. 
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Therefore, my research sought to explore the genomic expression profile of these two similar 
cells in a developmental model. 
Key to the success of my project was the ability to collect homogeneous populations of 
TRAP-positive cells adjacent to either the hypertrophic chondrocytes or the mineralizing bone. 
Laser capture microdissection enabled me to individually select cells and to capture them for 
subsequent analysis. After successfully capturing the TRAP-positive chondroclastic and 
osteoclastic cells, the ability to isolate and linearly amplify RNA from the small number of cells 
that I captured was another key to the success of this project. The RNA isolation and 
amplification protocol developed by Gibson et al (20), as modified by the Drissi laboratory, was 
critical for my ability to obtain sufficient amplified cDNA to enable me to run the qPCR to 
analyze the candidate genes. What I found was that there are clear differences between 
chondroclasts and osteoclasts in the expression profiles of the candidate genes I chose. These 
results supported and validated the hypothesis that chondroclasts and osteoclasts have different 
genomic profiles during embryonic development at time point E18.5. 
The candidate genes that I chose to examine had come from the set of differentially 
expressed genes that had been identified in the TRAP-positive cells within the healing mouse 
bone fracture (18). The genes that were observed in this study were chosen based on a variety of 
classifications. These include genes were involved in binding [Zfp595, P2rx5, Myo1D and 
Wnt5a], catalytic activity (Nxn, Dot1L, Aldh3a1 and Myo1D), enzyme regulator activity 
(Myo1D), transcription factor activity (Zfp595), receptor activity (P2rx5), a structural molecule 
(Myo1D) and transporter activity (P2rx5) (Table 6). In addition to similar classifications, these 
genes are co-expressed together and also have genetic interactions. P2rx5, Myo1D and Higd2a 
are known to be co-expressed together (26, 27) while Nxn and Wnt5a are also known to be co-
expressed together (27, 28). Higd2a and Thrsp have a known genetic interaction (29). The 
interaction maps in Figure 10, illustrate the broad range of interaction that these genes have. For 
instance, Hic1 indirectly interacts with Pax1, which directly interacts with Myo1D (Figure 10C). 
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It is through these classifications and interactions that we may come to understand what is 
happening in the microenvironment of these two clastic cells. 
When looking at the differences in expression of these genes between chondroclasts and 
osteoclasts, is important to note the microenvironments in which both cell types are found. To 
explain this, we have created a working model in order to demonstrate the kinds of interactions 
that are taking place in the microenvironments of these two cell types (Figure 11).  This model 
illustrates the lineage of chondroclasts and osteoclasts; both cell types arise from a hematopoietic 
stem cell, which is differentiated into a monocyte/macrophage precursor cell. These precursor 
cells, which are circulating in the blood stream, differentiate into pre-osteoclasts when stimulated 
by macrophage colony stimulating factor (M-CSF) (30). This pre-osteoclast further differentiates 
into an active osteoclast when stimulated by RANKL, giving rise to a cell that can now adhere to 
the bone and begin resorption (31). However, what is not known is what causes the 
monocyte/macrophage precursor cell to differentiate into the chondroclast. It is possible that M-
CSF and RANKL may also be involved in the differentiation of the chondroclast, but there could 
also be some other transcription factor, integrin or soluble factor that is responsible for the 
chondroclast lineage. 
In the future, we hope to examine more candidate genes and begin to build a genomic 
signature so that we can use this genomic signature to identify distinct signaling pathways that 
may regulate the two types of clastic cells. We would also like to look at additional time points 
(E15.5, E16.5 and post-natal), to examine whether changes in genetic expression of chondroclasts 
and osteoclasts vary temporally. It is important to do this because the expression of genes at an 
earlier time point may be different from that of a later time point, particularly since the 
microenvironment in which these cells are found change as endochondral ossification progresses. 
Lastly, we would like to interrogate the functionality of these genomic changes in both in vitro 
and in vivo models. In one such example, my laboratory has developed a conditional knockout 
mouse model for the gene, Dot1L. Since Dot1L plays a role in embryonic development and 
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hematopoiesis, knocking it out in chondroclasts and osteoclasts would tell us if and what type of 
skeletal phenotype the mouse may have. It will also tell us how severe the skeletal phenotype is; 
given that it is up-regulated in chondroclasts in the developmental model. It is critical to 
understand what is happening at this point as this will tell us why the two cell types are different.  
Understanding how the differential gene expression in these two cell types may play a 
role in a fracture repair model, for instance, could tell us whether knocking out one of these 
factors would improve or delay fracture healing. In the same way, we can examine whether these 
cells play a role in the other disease models, such as osteoarthritis or rheumatoid arthritis. As an 
example, Knowles et al conducted a study on rheumatoid arthritis using mature human clastic 
cells and observed what they termed chondroclasts on the deep surface of resorbed hyaline 
cartilage in this disease (15). Chondroclasts are predominantly found during the early stages 
endochondral ossification, so that by the time the bone is fully developed, there is very little to no 
trace of chondroclasts. In addition to this, chondroclasts are normally found on or near 
hypertrophic cartilage, rather than on the deep hyaline cartilage. It is possible that examining the 
genetic profile of chondroclasts that are found in the rheumatoid joint will help discover what 
genes are involved in signaling these chondroclasts to aberrantly appear in the sites of 
subchondral erosion. It is also possible that developing conditional knockout mouse models of 
these genes will lead to understanding how to prevent the breakdown of cartilage in rheumatoid 
arthritis.  
Thus, identifying and testing the functional differences in the genomic profile of 
osteoclasts and chondroclasts will be instrumental in developing new strategies to target these 
cells in diseases such as osteoarthritis, osteoporosis, rheumatoid arthritis and fracture. 
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Table 6: Classification of the genes used in my research using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) v6.7. (32, 33) 
 
  
	   33	  
 
 
 
 
  
  
 
 
A	   B	  
C	  
D	  
E	   F	  
G	   H	  
I	   J	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Figure 10: Known genetic interactions for each of the candidate genes. Figures 
developed using GeneCloud (Genecloud.org). A list of the top most related genes is 
plotted as a branching structure from the center. A secondary branch can occur if a 
gene in the graph is more related to a non-central gene than it is to the center gene. 
The font size of a branched gene indicates the relative strength of connection--always 
to the center gene. 
 
  
K	  
L	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Figure 11: Model of Chondroclast and Osteoclast Lineage 
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